Published in Urol Int on January 01, 2002
Post-biopsy rise in serum PSA. A potential tool for the dynamic evaluation of prostate cancer/prostatic intraepithelial neoplasia (PIN). Cancer Biol Ther (2003) 1.37
Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer (2005) 1.07
Liposome-mediated DNA vaccination. FEBS Lett (1997) 0.99
Vaccine entrapment in liposomes. Methods (1999) 0.92
Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome. Histopathology (2007) 0.89
Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int (2004) 0.86
Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer. Prostate Cancer Prostatic Dis (2000) 0.86
High yield incorporation of plasmid DNA within liposomes: effect on DNA integrity and transfection efficiency. J Drug Target (1996) 0.86
Influence of circumcision and sexual behaviour on PSA levels in patients attending a sexually transmitted disease (STD) clinic. Prostate Cancer Prostatic Dis (2001) 0.85
Does human papillomavirus play a role in the development of bladder transitional cell carcinoma? A comparison of PCR and immunohistochemical analysis. J Clin Pathol (2005) 0.84
Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. Hepatology (1998) 0.84
IPM chemotherapy in cytokine refractory renal cell cancer. Br J Cancer (2003) 0.84
DNA topoisomerase I and II expression in drug resistant germ cell tumours. Br J Cancer (2002) 0.81
GAMEC--a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours. Br J Cancer (2007) 0.79
p53 and MDM2 in germ cell cancer treatment response. J Clin Oncol (2002) 0.78
Detection of genetic alterations in primary bladder carcinoma with dual-color and multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet (2004) 0.77
Molecular characterisation of the t(1;15)(p22;q22) translocation in the prostate cancer cell line LNCaP. Cytogenet Genome Res (2006) 0.76
Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet (2002) 0.76
Sexual factors and prostate cancer. BJU Int (2004) 0.75
Cure of testicular germ cell cancer: an index of access to healthcare. Natl Med J India (2002) 0.75
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer (2003) 0.75
The frequency of intratubular embryonal carcinoma: implications for the pathogenesis of germ cell tumours. Histopathology (2004) 0.75
Comparative study of peptides isolated from class I antigen groove of urological specimens. a further step toward the future of peptide therapy in bladder cancer patients. Urol Int (2002) 0.75
Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer. Surg Oncol (2009) 0.75
Isolation of human leukocyte antigen (HLA)-associated peptide(s) in the absence of HLA-restricted specific cytolytic T lymphocytes. Urol Int (2002) 0.75
Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis. Osteoporos Int (2008) 0.75